Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-mesothelin CAR-T in Mesothelin-positive Advanced Solid Tumors
NCT05531708Phase 1Withdrawn
- Sponsor
- Shanghai Pudong Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-mesothelin CAR vector-transduced autologous T lymphocytes in solid tumor, sponsored by Shanghai Pudong Hospital. Primary endpoints: Treatment Emergent Adverse Events at 4 weeks, Treatment Related Adverse Events at 4 weeks and 1 more. Planned start Apr 2021; status: withdrawn.
02
Drugs
anti-mesothelin CAR vector-transduced autologous T lymphocytes
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05531708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531708.